Altimmune — Third Quarter 2026 Earnings Summary

Altimmune, Inc. reported a net loss of $31.6 million for the third quarter ended September 30, 2026, driven by increased research and development expenses related to its PERFORMA Phase 3 trial in MASH and RESTORE Phase 2 trial in ALD. The company holds $480 million in cash, cash equivalents, and investments as of the end of the quarter. Clinical progress includes the ongoing global PERFORMA Phase 3 trial in MASH with topline data anticipated in 2029, positive RECLAIM Phase 2 data in AUD presented at AASLD, and a scheduled End-of-Phase 2 meeting with the FDA for the AUD program in December 2026. Additionally, enrollment is complete for the RESTORE Phase 2 trial in ALD, with topline data expected in the second half of 2027.